News
3 High-Yield S&P 500 Dividend Stocks That You Can Buy With $100 Right Now
This has been an amazing year for stocks, with a 12.6% rise in the benchmark S&P 500 index. Fortunately for us value-conscious investors, the latest bull run has been mostly constrained to a handful
Want $1,000 in Dividend Income? Here's How Much You Have to Invest in Pfizer Stock
Pfizer (NYSE: PFE) may not be the must-have pharmaceutical investment it was at one point. If your priority is reliable divided income, however, the drugmaker remains a rock-solid pick. Not only has
3 No-Brainer Stocks to Buy in July
July is for barbecues, fireworks, and vacations. Many people don't want to think too hard about anything. Three Fool.com contributors think they have solutions for those investors who don't want to
EQS-News: Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
The Smartest Dividend Stocks to Buy With $250 Right Now
Dividend stocks pay you regularly regardless of how the share price fluctuates. Ideally, of course, the share price will move steadily higher over time and make you money in two ways.
The good news
Billionaires Are Buying Up Beaten-Down AT&T Stock. Should Dividend-Seeking Investors Follow Their Lead?
Billionaire investors don't necessarily need quarterly payments from dividend stocks to cover their day-to-day expenses, but they buy them anyway. That's because businesses that distribute a portion
Down 55%, Is Pfizer a Good Dividend Stock to Buy on the Dip?
The past few years have been tough ones for investors holding shares of Pfizer (NYSE: PFE). The Big Pharma stock is down by more than half from the peak it set in late 2021.
Pfizer's stock price was
After a Big Win, Is Sarepta Therapeutics Stock a Buy?
On June 20, the Food and Drug Administration (FDA) gave Sarepta Therapeutics (NASDAQ: SRPT) exactly what it wanted. The agency upgraded the status of its gene therapy for Duchenne muscular dystrophy
3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With $100 in July
The benchmark S&P 500 index keeps breaking new records thanks in large part to a handful of stocks at the top. Luckily for income-seeking investors, there are some highly reliable dividend stocks
Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).
Vertex Pharmaceuticals (NASDAQ: VRTX) transformed the world of cystic fibrosis (CF) treatment when it launched its first product for the disease 12 years ago. Since then, it's built a CF treatment
1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever
Investing in equity markets is a reliable, wealth-growing strategy. In the past 33 years, the S&P 500's average annual return is about 10.6%. It's hard to find a return much better than that
Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio
Eli Lilly (NYSE: LLY) has become a big name in the anti-obesity market with the recent approval of Zepbound, which is likely to rake in billions in revenue alongside Mounjaro, the company's diabetes
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?
With Vertex Pharmaceuticals (NASDAQ: VRTX) announcing on June 21 that its therapy VX-880 helped nearly all of the patients with diabetes in a clinical trial to reduce or eliminate their need for
Up Halfway Through 2024, Can AT&T's Stock Continue Its Momentum to Close the Year?
Over the past two decades, the road has been rocky for AT&T (NYSE: T) investors, with the stock price only up close to 5% (not including dividends). This year has been a much-appreciated change of
Can These 2 Ultra-High-Yield Dividend Stocks Outperform the S&P 500 in 2024?
Ultra-high-yield dividend stocks, or companies with annualized payouts above the 5% mark, tend to underperform the broader markets over periods of less than five years. The core reason is that an
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?
When a company obtains positive news from the Food and Drug Administration (FDA), such as the approval of a treatment or a label expansion, it can mark a milestone for the business and lead to
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
A few years ago, Eli Lilly (NYSE: LLY) was far from the hottest stock in the biopharmaceutical world. But times have changed. Today, Lilly ranks as the biggest healthcare company in the world. It
1 Soaring Growth Stock to Buy and Hold for 10 Years
Most investors know the phrase "buy low, sell high." It's a fine piece of investing wisdom, but it isn't as straightforward as it seems. Even a company whose shares are performing well can be
Almirall Launches Act4Impact – its Updated Sustainability Strategy Setting Ambitious Targets for 2030
Almirall S.A. (BME: ALM), a global pharmaceutical company dedicated to medical dermatology, launched its new sustainability strategy Act4Impact 2030 today. The updated strategy aims at transforming
Can Retirees Still Trust AT&T's 5.8% Dividend Yield?
U.S. wireless carrier AT&T (NYSE: T) is a polarizing stock among investors. Shares are down nearly 30% in price over the past decade, which is a tough pill to swallow. However, include AT&T's famous
1 Underwhelming Stat That May Have You Thinking Twice About Buying Pfizer's Stock
Pfizer (NYSE: PFE) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at
2 High-Yielding Healthcare Stocks to Buy With $1,000 in July
It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment
Viking Therapeutics Stock Is Up by 154% Since January -- Can It Double Again in the Second Half of the Year?
Few biotech companies have made more noise than Viking Therapeutics (NASDAQ: VKTX) this year, and that's saying something. The drugmaker had been a relatively small and unknown player in the
3 Magnificent Stocks Retirees Can Buy and Hold Forever
Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments.
Three